Comerica Securities Inc. bought a new position in Eli Lilly And Co (NYSE:LLY) during the third quarter, according to its most recent Form 13F filing with the SEC. The firm bought 2,300 shares of the company’s stock, valued at approximately $247,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Gyroscope Capital Management Group LLC raised its position in shares of Eli Lilly And Co by 0.5% during the 3rd quarter. Gyroscope Capital Management Group LLC now owns 89,849 shares of the company’s stock valued at $10,334,000 after buying an additional 469 shares during the period. Bbva Compass Bancshares Inc. raised its position in shares of Eli Lilly And Co by 5.3% during the 3rd quarter. Bbva Compass Bancshares Inc. now owns 9,349 shares of the company’s stock valued at $1,003,000 after buying an additional 474 shares during the period. Pure Financial Advisors Inc. raised its position in shares of Eli Lilly And Co by 18.3% during the 3rd quarter. Pure Financial Advisors Inc. now owns 3,166 shares of the company’s stock valued at $340,000 after buying an additional 490 shares during the period. Balasa Dinverno & Foltz LLC raised its position in shares of Eli Lilly And Co by 15.9% during the 3rd quarter. Balasa Dinverno & Foltz LLC now owns 3,629 shares of the company’s stock valued at $389,000 after buying an additional 499 shares during the period. Finally, Legacy Private Trust Co. raised its position in shares of Eli Lilly And Co by 5.2% during the 3rd quarter. Legacy Private Trust Co. now owns 10,365 shares of the company’s stock valued at $1,112,000 after buying an additional 508 shares during the period. 76.17% of the stock is currently owned by institutional investors and hedge funds.

In related news, major shareholder Eli & Co Lilly sold 700,000 shares of Eli Lilly And Co stock in a transaction that occurred on Tuesday, November 6th. The shares were sold at an average price of $14.00, for a total value of $9,800,000.00. Following the completion of the sale, the insider now owns 3,148,647 shares in the company, valued at approximately $44,081,058. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Donald A. Zakrowski sold 600 shares of Eli Lilly And Co stock in a transaction that occurred on Tuesday, September 4th. The shares were sold at an average price of $105.57, for a total transaction of $63,342.00. Following the completion of the sale, the insider now owns 3,530 shares of the company’s stock, valued at approximately $372,662.10. The disclosure for this sale can be found here. Insiders sold a total of 1,881,684 shares of company stock valued at $133,274,076 in the last quarter. 0.11% of the stock is owned by insiders.

Eli Lilly And Co stock opened at $112.21 on Friday. Eli Lilly And Co has a fifty-two week low of $73.69 and a fifty-two week high of $116.61. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.91 and a quick ratio of 1.09. The company has a market capitalization of $116.23 billion, a P/E ratio of 26.22, a P/E/G ratio of 1.75 and a beta of 0.29.

Eli Lilly And Co (NYSE:LLY) last posted its earnings results on Tuesday, November 6th. The company reported $1.39 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.35 by $0.04. Eli Lilly And Co had a net margin of 1.85% and a return on equity of 42.84%. The firm had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. During the same quarter last year, the firm earned $1.05 EPS. The firm’s revenue for the quarter was up 7.1% on a year-over-year basis. On average, sell-side analysts expect that Eli Lilly And Co will post 5.57 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, December 10th. Investors of record on Thursday, November 15th will be issued a $0.5625 dividend. The ex-dividend date is Wednesday, November 14th. This represents a $2.25 annualized dividend and a yield of 2.01%. Eli Lilly And Co’s dividend payout ratio (DPR) is presently 52.57%.

Several research firms have recently commented on LLY. Credit Suisse Group raised shares of Eli Lilly And Co from an “underperform” rating to a “neutral” rating in a research report on Wednesday, October 31st. ValuEngine lowered shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Tuesday, November 6th. JPMorgan Chase & Co. set a $123.00 price target on shares of Eli Lilly And Co and gave the company a “buy” rating in a research report on Friday, October 5th. Bank of America lifted their price target on shares of Eli Lilly And Co from $90.00 to $94.00 and gave the company a “neutral” rating in a research report on Wednesday, July 25th. Finally, Cantor Fitzgerald set a $100.00 price target on shares of Eli Lilly And Co and gave the company a “buy” rating in a research report on Tuesday, July 24th. Nine investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $111.19.

WARNING: This article was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://theolympiareport.com/2018/11/11/comerica-securities-inc-takes-247000-position-in-eli-lilly-and-co-lly.html.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Recommended Story: Initial Public Offering (IPO)

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.